Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
10 09 2020
Historique:
received: 09 07 2020
accepted: 09 09 2020
pubmed: 11 9 2020
medline: 2 3 2021
entrez: 10 9 2020
Statut: epublish

Résumé

Properdin stabilizes the alternative C3 convertase (C3bBb), whereas its role as pattern-recognition molecule mediating complement activation is disputed for decades. Previously, we have found that soluble collectin-12 (sCL-12) synergizes complement alternative pathway (AP) activation. However, whether this observation is C3 dependent is unknown. By application of the C3-inhibitor Cp40, we found that properdin in normal human serum bound to

Identifiants

pubmed: 32909942
doi: 10.7554/eLife.60908
pii: 60908
pmc: PMC7511233
doi:
pii:

Substances chimiques

Collectins 0
Complement C3 0
Properdin 11016-39-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2020, Zhang et al.

Déclaration de conflit d'intérêts

JZ, LS, DP, AL, GA, TM, YM, PG No competing interests declared, JL inventor of patents (Patent Number: 9630992) and/or patent applications 426 (Application Number: 15/126,937) that describe the use of complement inhibitors for therapeutic purposes, founder of Amyndas Pharmaceuticals, which is developing complement inhibitors (i.e., third-generation compstatins) for clinical applications, and inventor of the compstatin technology licensed to Apellis Pharmaceuticals (i.e., 4[1MeW]7W/POT-4/APL-1 and PEGylated derivatives).

Références

J Immunol. 1989 Jan 1;142(1):202-7
pubmed: 2909614
J Immunol Res. 2019 Jul 29;2019:9164202
pubmed: 31482100
Clin Chem Lab Med. 2014 Mar;52(3):453-61
pubmed: 24114918
J Biol Chem. 2011 Feb 4;286(5):3405-17
pubmed: 21106539
J Exp Med. 1976 Oct 1;144(4):1076-93
pubmed: 978134
Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):1-14
pubmed: 27864148
J Exp Med. 1958 Oct 1;108(4):515-35
pubmed: 13575682
Infect Immun. 2011 Feb;79(2):724-31
pubmed: 21134964
J Immunol. 2008 Mar 1;180(5):3313-8
pubmed: 18292556
J Biol Chem. 2006 Jan 27;281(4):2128-32
pubmed: 16301317
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5301-6
pubmed: 24706855
Eur J Biochem. 1994 Feb 1;219(3):759-64
pubmed: 8112326
J Community Hosp Intern Med Perspect. 2015 Feb 03;5(1):26322
pubmed: 25656673
J Biol Chem. 1992 Oct 5;267(28):20435-43
pubmed: 1400362
J Innate Immun. 2013;5(3):242-50
pubmed: 23220946
J Immunol. 2015 Oct 1;195(7):3365-73
pubmed: 26290605
Annu Rev Immunol. 2010;28:131-55
pubmed: 19947883
J Immunol. 2015 Aug 1;195(3):1171-81
pubmed: 26116506
Cell Microbiol. 2012 Jun;14(6):914-36
pubmed: 22309204
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E534-E539
pubmed: 28069958
J Exp Med. 1975 Oct 1;142(4):856-63
pubmed: 1185108
J Immunol. 2016 Jun 1;196(11):4671-4680
pubmed: 27183616
Mol Immunol. 2000 Jun;37(8):467-78
pubmed: 11090881
J Biol Chem. 2001 Nov 23;276(47):44222-8
pubmed: 11564734
J Immunol. 1993 Sep 1;151(5):2521-8
pubmed: 8360474
Blood. 2014 Mar 27;123(13):2094-101
pubmed: 24497537
Immunol Lett. 2019 Feb;206:28-32
pubmed: 30521839
Front Immunol. 2019 Aug 22;10:2007
pubmed: 31507604
Science. 1954 Aug 20;120(3112):279-85
pubmed: 13186838
J Biol Chem. 2009 Oct 9;284(41):28263-75
pubmed: 19632990
Infect Dis (Lond). 2015 Apr;47(4):203-8
pubmed: 25650730
J Biol Chem. 2005 Jun 17;280(24):22993-9
pubmed: 15845541
J Infect Dis. 2018 Sep 8;218(8):1291-1295
pubmed: 29800140
J Immunol. 2010 Jul 1;185(1):507-16
pubmed: 20530262
Mol Immunol. 2008 Jun;45(11):3278-88
pubmed: 18423602
EMBO J. 2017 Apr 13;36(8):1084-1099
pubmed: 28264884
Biochim Biophys Acta. 2014 Dec;1840(12):3345-56
pubmed: 25199873
J Immunol. 2013 Aug 1;191(3):1324-33
pubmed: 23817411
J Immunol. 2013 Jun 15;190(12):6457-67
pubmed: 23677468
Breast Cancer Res Treat. 2007 Jan;101(2):161-74
pubmed: 16850248
Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9023-8
pubmed: 18579773
J Neurosci Res. 2006 Sep;84(4):874-90
pubmed: 16868960
J Biol Chem. 2011 Feb 18;286(7):5359-67
pubmed: 21135110
Biochem Biophys Res Commun. 2001 Feb 2;280(4):1028-35
pubmed: 11162630
Acta Crystallogr F Struct Biol Commun. 2019 Feb 1;75(Pt 2):0
pubmed: 30713161
J Immunol. 2008 Jun 1;180(11):7613-21
pubmed: 18490764
J Immunol. 2012 Sep 1;189(5):2606-13
pubmed: 22851705
Antioxid Redox Signal. 2013 Jun 10;18(17):2352-63
pubmed: 22900885
J Immunol. 1997 May 1;158(9):4444-51
pubmed: 9127010
J Biol Chem. 2009 Feb 6;284(6):3956-65
pubmed: 19073604
J Exp Med. 1975 Sep 1;142(3):760-72
pubmed: 1165475
Scand J Clin Lab Invest. 2012 Feb;72(1):1-13
pubmed: 22060747
J Biol Chem. 2011 Mar 11;286(10):7822-9
pubmed: 21205820
Sci Rep. 2018 Feb 28;8(1):3821
pubmed: 29491476
J Innate Immun. 2014;6(4):417-25
pubmed: 24355864
Sci Rep. 2017 Mar 20;7:44794
pubmed: 28317919

Auteurs

Jie Zhang (J)

The Laboratory of Molecular Medicine, Department of Clinical Immunology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.

Lihong Song (L)

The Laboratory of Molecular Medicine, Department of Clinical Immunology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Department of Pharmaceutical Science, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.

Dennis V Pedersen (DV)

Department of Molecular Biology and Genetics, Center for Structural Biology, Aarhus University, Aarhus, Denmark.

Anna Li (A)

The Laboratory of Molecular Medicine, Department of Clinical Immunology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.

John D Lambris (JD)

Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.

Gregers Rom Andersen (GR)

Department of Molecular Biology and Genetics, Center for Structural Biology, Aarhus University, Aarhus, Denmark.

Tom Eirik Mollnes (TE)

Department of Immunology, Oslo University Hospital, and University of Oslo, Oslo, Norway.
Research Laboratory, Nordland Hospital, K. G. Jebsen TREC, University of Tromsø, Bodø, Norway.
Center of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway.

Ying Jie Ma (YJ)

The Laboratory of Molecular Medicine, Department of Clinical Immunology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Peter Garred (P)

The Laboratory of Molecular Medicine, Department of Clinical Immunology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH